Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Coherus Oncology Inc shares valued at $73,881 were sold by Wahlstrom Mats on May 23 ’25. At $0.74 per share, Wahlstrom Mats sold 99,988 shares. The insider’s holdings dropped to 0 shares worth approximately $0.0 following the completion of this transaction.
As published in a research note from UBS on August 16, 2024, Coherus Oncology Inc [CHRS] has been rated down from a Buy to a Neutral and the price target has been revised to $1.50 from $4. Analysts at Robert W. Baird started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid November. As of November 08, 2023, Maxim Group has decreased its “Buy” rating to a “Hold” for CHRS. Earlier on July 24, 2023, Citigroup initiated its rating. Their recommendation was “a Buy” for CHRS stock.
Analyzing CHRS Stock Performance
On last trading session,, Coherus Oncology Inc [NASDAQ: CHRS] plunged -0.12% to $0.87. The stock’s lowest price that day was $0.8437, but it reached a high of $0.8886 in the same session. During the last five days, there has been a surge of approximately 9.07%. Over the course of the year, Coherus Oncology Inc shares have dropped approximately -31.72%. Shares of the company reached a 52-week high of $1.7699 on 01/06/25 and a 52-week low of $0.7100 on 06/23/25.
Support And Resistance Levels for Coherus Oncology Inc (CHRS)
According to the 24-hour chart, there is a support level at 0.8444, which, if violated, would cause prices to drop to 0.8216. In the upper region, resistance lies at 0.8893. The next price resistance is at 0.9114. RSI (Relative Strength Index) is 59.03 on the 14-day chart, showing neutral technical sentiment.
Is Coherus Oncology Inc subject to short interest?
Stocks of Coherus Oncology Inc saw a sharp steep in short interest on 2025-06-13 dropping by -1.17 million shares to 31.94 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 33.12 million shares. A decline of -3.68% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 21.85 of the overall float, the days-to-cover ratio (short ratio) decline to 21.85.
Which companies own the most shares of Coherus Oncology Inc (CHRS)?
In terms of Coherus Oncology Inc share price expectations, FactSet research, analysts set an average price target of 1.05 in the next 12 months, up nearly 20.69% from the previous closing price of $0.87. Analysts anticipate Coherus Oncology Inc stock to reach 1.05 by 2025, with the lowest price target being 1.05. In spite of this, 5 analysts ranked Coherus Oncology Inc stock as Buy at the end of 2025. On May 01, 2023, Truist assigned a price target of “a Buy” to the stock and initiated coverage with a $24.
